NASDAQ:IRTC - Irhythm Technologies Stock Price, Forecast & News

Irhythm Technologies trades on the NASDAQ under the ticker symbol "IRTC."

Irhythm Technologies Inc (NASDAQ:IRTC) released its earnings results on Tuesday, November, 5th. The company reported ($0.74) EPS for the quarter, missing the Zacks' consensus estimate of ($0.40) by $0.34. The firm had revenue of $55.96 million for the quarter, compared to analyst estimates of $53.76 million. Irhythm Technologies had a negative return on equity of 67.44% and a negative net margin of 26.45%. The company's revenue for the quarter was up 46.9% compared to the same quarter last year. During the same period last year, the firm earned ($0.43) EPS. View Irhythm Technologies' Earnings History.

Irhythm Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for Irhythm Technologies.

Irhythm Technologies updated its FY 2019 Pre-Market earnings guidance on Monday, December, 23rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $213-214 million, compared to the consensus revenue estimate of $216.89 million.

11 equities research analysts have issued 1-year price objectives for Irhythm Technologies' shares. Their forecasts range from $75.00 to $125.00. On average, they anticipate Irhythm Technologies' stock price to reach $103.00 in the next year. This suggests a possible upside of 16.2% from the stock's current price. View Analyst Price Targets for Irhythm Technologies.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Irhythm Technologies in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Irhythm Technologies.

Media stories about IRTC stock have been trending somewhat negative recently, according to InfoTrie. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Irhythm Technologies earned a daily sentiment score of -1.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Irhythm Technologies.

Some companies that are related to Irhythm Technologies include Novocure (NVCR), ABIOMED (ABMD), Hill-Rom (HRC), Penumbra (PEN), Haemonetics (HAE), Globus Medical (GMED), Integra Lifesciences (IART), Tandem Diabetes Care (TNDM), NuVasive (NUVA), Nevro (NVRO), ICU Medical (ICUI), Cantel Medical (CMD), Glaukos (GKOS), Merit Medical Systems (MMSI) and Inspire Medical Systems (INSP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Irhythm Technologies investors own include Alibaba Group (BABA), Twilio (TWLO), Tandem Diabetes Care (TNDM), DexCom (DXCM), NVIDIA (NVDA), Splunk (SPLK), Canopy Growth (CGC), Paycom Software (PAYC), Netflix (NFLX) and Paypal (PYPL).

(IRTC) raised $76 million in an initial public offering on Thursday, October 20th 2016. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Irhythm Technologies' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Cerebellum GP LLC (0.01%) and Exchange Traded Concepts LLC (0.00%). Company insiders that own Irhythm Technologies stock include Bruce G Bodaken, David A Vort, Derrick Sung, Kevin M King, Matthew C Garrett, Merz Cathleen Noel Bairey, Raymond W Scott and Vijay K Lathi. View Institutional Ownership Trends for Irhythm Technologies.

IRTC stock was purchased by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC and Cerebellum GP LLC. View Insider Buying and Selling for Irhythm Technologies.

Shares of IRTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IRTC stock can currently be purchased for approximately $88.62.

Irhythm Technologies has a market capitalization of $2.36 billion and generates $147.29 million in revenue each year. The company earns $-48,280,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis. Irhythm Technologies employs 748 workers across the globe.View Additional Information About Irhythm Technologies.

The official website for Irhythm Technologies is http://www.irhythmtech.com/.

Irhythm Technologies' mailing address is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. The company can be reached via phone at 415-632-5700 or via email at [email protected]